RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Metachronous colorectal cancer have a similar microsatellite instability frequency but a lower infiltration of lymphomononuclear cells than primary lesions.
Metachronous colorectal cancer have a similar microsatellite instability frequency but a lower infiltration of lymphomononuclear cells than primary lesions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究显示,出乎意料的是,异时性结直肠癌与散发性结直肠癌的微卫星不稳定频率相似。此外,我们的数据提示,免疫微环境改变可能是允许异时性结直肠癌发生的关键因素。事实上,淋巴单核细胞缺失可能是对肿瘤新抗原免疫应答微弱的基础,从而为第二原发结直肠癌的发生创造了条件。
异时性结直肠癌风险增加通常与Lynch综合征中发生的微卫星不稳定性相关。然而,并非所有异时性结直肠癌患者都具有微卫星不稳定性。TIL(肿瘤浸润淋巴细胞)密度是结直肠癌患者预后的独立预测因子,一个引人入胜的假说是它们可能参与异时性结直肠癌的发生。本研究旨在分析散发性与异时性结直肠癌的肿瘤微环境和肿瘤突变频率。
本回顾性研究调取了2015年至2019年间连续接受手术的一系列结直肠癌患者的临床和病理记录。我们将异时性结直肠癌定义为在原发癌出现至少1年后发生的第二原发结直肠癌,将散发性结直肠癌定义为未发生异时性结直肠癌者。所有病例均进行了肿瘤内淋巴单核细胞浸润的组织学检查、MLH1、PMS2、MSH2和MSH6的免疫组化检测,以及BRAF、KRAS和NRAS的突变分析。对散发性结直肠癌与异时性结直肠癌进行了比较。由于样本量较小,采用非参数检验进行比较。
在这项研究中,2015年至2019年间,帕多瓦医院集团普外科共为238例结直肠癌患者实施了手术。我们识别出26例异时性结直肠癌患者,其中仅3例在原发结直肠癌后接受过辅助治疗。异时性结直肠癌与散发性结直肠癌在肿瘤分期方面未观察到差异。异时性结直肠癌与散发性结直肠癌中错配修复基因缺陷及微卫星不稳定性频率相似(P = .77)。同样,两组中BRAF和KRAs的突变频率也相似(分别为P = .75和P = .21)。相反,异时性结直肠癌患者中肿瘤内缺乏淋巴单核细胞浸润的情况更为常见(P = .004),且他们往往具有更高的NRAS突变频率(P = .06)。
An increased risk of metachronous colorectal cancer is usually associated with microsatellite instability occurring in Lynch syndrome. However, not all patients with metachronous colorectal cancer have microsatellite instability. The density of tumor-infiltrating lymphocytes is an independent predictor of outcome in patients with colorectal cancer, and a fascinating hypothesis is that they can be involved in the onset of metachronous colorectal cancer. The aim of this study was to analyze the tumor microenvironment and tumor mutation frequency in sporadic and metachronous colorectal cancer.
The clinical and pathological records of a series of consecutive colorectal cancer patients who were operated on from 2015 to 2019 were retrieved for this retrospective study. We defined metachronous colorectal cancer as a second colorectal cancer that appeared at least 1 year after the primary one, and sporadic colorectal cancer as those that did not have a metachronous colorectal cancer. Histology for the infiltration of intratumoral lymphomononuclear cells, immunohistochemistry for MLH1, PMS2, MSH2, and MSH6, and mutational analysis of BRAF, KRAS, and NRAS were all performed. Sporadic colorectal cancer and metachronous colorectal cancer were compared. Nonparametric tests were used for small sample size comparison.
In the study, 238 patients were operated on for colorectal cancer at the General Surgery Unit of the Azienda Ospedaliera di Padova from 2015 to 2019. We identified 26 patients with metachronous colorectal cancer, and only 3 of them had had adjuvant therapy after the primary colorectal cancer. No difference was observed in terms of cancer stage between metachronous and sporadic colorectal cancer. Mismatch repair gene deficiencies and microsatellite instability frequency was similar in metachronous colorectal cancer and in sporadic colorectal cancer (P = .77). Likewise, the mutation frequency of BRAF and KRAs was similar in the 2 groups (P = .75 and P = .21, respectively). To the contrary, the absence of infiltration of lymphomononuclear cells within the tumor (P = .004) in patients with metachronous colorectal cancer was more frequent and they tended to have a higher frequency of NRAS mutation (P = .06).
Our study showed that, rather unexpectedly, microsatellite instability frequency was similar in metachronous and sporadic colorectal cancer. Moreover, our data suggest that an altered immune microenvironment may be a crucial factor, permitting the occurrence of metachronous colorectal cancer. In fact, the absence of lymphomononuclear cells can be the substrate for a weak immune response to cancer neoantigens, opening the way to a second primary colorectal cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。